MKI67 and breast carcinoma: Thus, in clinical practice, a surrogate classification of luminal breast cancer is widely performed based on immunohistochemical evaluation for ER, progesterone receptor (PR; an oestrogen‐response marker) and Ki67 (a proliferative marker), serving as important criteria for therapy decisions.4